Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

ASCO 2023: Latest in PARP inhibitors in prostate cancer

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

ASCO 2023: Breast cancer research highlights

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer

Optimising cervical cancer care in Nigeria

Choosing cancer medicines wisely in Africa

Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours